Carbon-Nitrogen Lyases TRIZ Cases

Modular rGlyP engineering and NADPH balancing enable aerobic growth on formate, methanol, methane, or CO2 for sustainable bioproduction.

Engineered microorganisms convert methane into multi-carbon fuels and chemicals, cutting reliance on petroleum and food-based feedstocks.

Site-specific PEGylation helps phenylalanine lyase retain activity, lower immunogenicity, and sustain plasma exposure for PKU treatment.

Engineered bacteria use an enzymatic biosynthetic pathway to make enantiopure L-piperazic acid at lower cost and with fewer synthetic steps.

Targeted PAL amino acid substitutions improve catalytic activity, thermal stability, and aggregation resistance for more durable PKU therapy.

Light-responsive amplifier and inverter circuits boost gene control under poor light penetration, enabling multi-phase microbial fermentation.

Modular INDS expression and cell-free production improve indigoidine yield and scalability in heterologous host cells.

Mutating L-threonine dehydratase at residue 381 reduces isoleucine feedback inhibition and raises microbial L-isoleucine yield.

An enzymatic route converts L-homoserine and methanethiol directly to L-methionine, avoiding unstable O-acyl intermediates and inhibitory byproducts.

Targeted DapB substitutions raise L-threonine yield while preserving microbial growth and avoiding severe lysine pathway disruption.

Engineered microbial host cells use heterologous enzymes and fermentation to produce tropane alkaloids without plant monocultures.

Engineered P. putida combines phenylpropanoid tolerance with recombinant benzalacetone reductase to improve frambinone and zingerone production.

See how PAL variants, BesC, and decarboxylase enzymes convert inexpensive L-lysine into butadiene through a cost-saving pathway.

Weakened serine dehydratase redirects Corynebacterium metabolism to support higher purine nucleotide yield during fermentation.

Thermostable PAL variants maintain phenylalanine-degrading activity under heat stress, supporting enzyme-based PKU treatment.

Engineered gut bacteria metabolize phenylalanine into non-toxic compounds, easing dietary restrictions in PKU management.

LX-109S epoxy resin forms stable covalent links with enzymes while preserving activity and improving reuse in immobilization.

A mutated AroF-I gene enables tyrosine overproduction in Pseudomonas putida for coumaric acid and frambinone synthesis with improved tolerance.

Inactivating LysE retains L-arginine inside engineered microorganisms, increasing substrate availability for fermentative GAA and creatine production.

A recombinant microorganism channels threonine into glycine and acetyl-CoA while reducing competing metabolic pathways.

Cyclodextrin additives form inclusion complexes with hydrophobic sphingoid bases, resolving poor aqueous solubility and boosting yeast cultivation yields.

Replacing hazardous chemical synthesis, recombinant microbes convert styrene into enantiopure 2-phenylglycinol via enzyme cascades for sustainable production.

A glutamic acid to glutamine mutation at position 427 alters the active site polar environment to boost aspartase enzyme activity.

Heterologous PntAB transhydrogenase expression in Corynebacterium glutamicum enhances NADPH availability for fermentative L-lysine synthesis.

Increasing aspartate supply through gene copy number expansion overcomes intracellular feedback inhibition to raise L-arginine productivity.

Segmented enzymatic conversion of 4-nitrophenylalanine to 4-aminocinnamic acid improves reaction rate and efficiency over conventional microbial routes.

A segmented enzymatic pathway in recombinant microbes converts renewable substrates to 2-phenylethanol, resolving low yield and scalability bottlenecks.

Recombinant hosts expressing tyrosine ammonia lyase increase phenylpropanoid yields by redirecting carbon flux away from side product formation.

Water extraction with asparaginase and aspartase degrades acrylamide precursors, avoiding complex pretreatments that alter organoleptic properties.

Cell disruption releases intracellular EDDS synthase while fumarate inhibition suppresses competing fumarase activity to maximize substrate conversion.

Inactivating degradation genes and enhancing metabolic flux increases bacterial tolerance to high serine concentrations.

Replacing native photorespiration with a synthetic beta-hydroxyaspartate pathway eliminates CO2 release and reduces energy loss during carbon fixation.

Empty microcompartments sequester cytotoxic proteins within bacterial cells to enable safe production.

Multi-enzyme systems attached to nanoparticles transfer isotopes via enzymatic cascades, resolving the trade-off between efficiency and site-specific control.

Whole-cell biocatalysts convert L-phenylalanine to styrene via PAL and Fdc1 enzymes, avoiding toxicity limits for 18.3 g/L titres.

Engineered bacteria expressing mutant phenylalanine ammonia lyase metabolize phenylalanine, eliminating restrictive diets and cofactor side effects.

Engineered tyrosine ammonia lyase polypeptides catalyze tyrosine metabolism to produce coumaric acid.

A recombinant myxoma virus expresses argininosuccinate synthase 1 to reconstitute the arginine biosynthetic pathway within tumor cells.

Engineering recombinant yeast strains with reduced mitochondrial enzyme activities to increase isobutanol yields.

Engineered microorganisms metabolize renewable sugar feedstocks to biosynthesize methacrylic acid and its precursors through specific enzymatic pathways.

Hyperbranched polyglycerol conjugates shield proteins from stomach acid and proteases, enabling stable oral delivery.

Ethyl cellulose microcapsules containing phenylalanine ammonia lyase reduce blood L-phenylalanine levels via oral administration.

Replacing harsh chemical synthesis, aspartase converts butenoic acid to R-3-aminobutyric acid, eliminating heavy metal pollution and reducing reaction time.

Recombinant yeast ferments processed feedstock slurry to produce renewable hydrocarbon compositions.

Genetically engineered bacteria metabolize phenylalanine into non-toxic compounds via oral administration.

Engineered host cells expressing feedback-resistant HisG, HisD, and HisC enzymes alongside folate mediator genes to boost histidine synthesis.

Modulating specific enzymatic activities in microbial hosts directs protein synthesis toward canonical branched-chain amino acids.

Engineered Lactobacillus reuteri strains metabolize ethanolamine to produce antimicrobial acetaldehyde, outcompeting Salmonella typhimurium in the gut.

Coupling enzyme activity to cell growth through the SAM cycle selects for improved methyltransferase function and boosts metabolite production.